Craig Venter died on Tuesday April 29 in San Diego at age seventy-nine, after what the institute he founded called "unexpected side effects from treatment of recently diagnosed cancer." [1] On Friday May 2, the J. Craig Venter Institute named Anders M. Dale, PhD, as its president. [2] The interval between the death and the announcement was approximately ninety-six hours. The Sunday paper carried the brief on the appointment; today's piece is about the institutional shape of that interval.

Dale is not a stranger to the building. He had been named JCVI's president-and-board-member on April 2, 2025, more than a year before Venter's death — appointed while Venter was alive, board-confirmed, and operationally engaged. [3] The Friday announcement was less a hire than a constitutional handoff. The release named him as president, faculty, and member of the board; the obituary release the same week named Venter as the founder, board chair, and CEO whose absence the institute would now absorb without a search. [1] [2]

Dale's path is, on its face, an unusual one for a genome shop. He arrived from the University of California, San Diego, where he was professor of neurosciences, radiology, psychiatry, cognitive science, and data science. He authored more than six hundred peer-reviewed publications with more than two hundred thousand citations. [4] He brought twenty-two scientists and software engineers with him from UCSD, including the management of the Adolescent Brain Cognitive Development study and the HEALthy Brain and Child Development study — the two largest long-term studies of brain development in the United States. [4] What Venter built was a private institute optimized for genome-scale sequencing and synthetic biology. What Dale brings is a neuroimaging-plus-genomics integration that merges phenotype with genotype. JCVI's new line, on its own website, names "phenotype and genotype data to improve health outcomes" as the center of the institute's new direction. [3]

The succession matters because of its negative space. The National Science Board fired twenty-two of its twenty-four members by terse email ten days ago. Today is Day Ten. There is no academy lawsuit. There is no replacement appointment. There is no public framework. The federal scientific advisory body that authorizes NSF priorities — by statute, not by custom — has been operating without a quorum since April 24. [5]

The contrast is not subtle. A private nonprofit institute funded primarily by philanthropic capital had a published succession plan in place when its founder died. A statutorily constituted federal advisory board, funded by the U.S. Treasury, did not have one when its membership was administratively terminated. JCVI named its president inside four days. The federal government has not named twenty-two members in ten.

There is no scandal in the comparison. JCVI's hand was forced by mortality. NSB's hand was forced by the White House. The relevant distinction is what each institution had ready when the forcing event arrived. Dale's appointment was the result of a transition planned a year in advance — Venter's "Memories of" essay published April 30 made clear that Venter had spent his final months thinking about the institute's continuity. [6] The NSB had been operating under the assumption that its statute and its standing membership would continue to function until they were replaced. They did not.

What Dale inherits is the harder problem. JCVI is roughly 220 staff across La Jolla and Rockville, a budget mostly funded by federal grants and philanthropy, with a research stack that runs from genome assembly through synthetic biology. The institute was, in its early years, more associated with Venter than any other living person. The transition to a Dale-era JCVI requires a substantive scientific re-anchoring. Dale's letter to staff [3] focused on continuity — "Craig believed that science moves forward when people are willing to think differently, move decisively, and build what doesn't yet exist." It also focused on the institutional asset Venter built: a culture in which fast moves were normal.

The institute's research portfolio remains large. The Pacific-Wildland-Lab gap that the paper has tracked in federal scientific instrument silence does not run inside JCVI's walls; it runs in the federal labs. Dale's first month will be spent assuring the federal program officers funding JCVI grants — at NIH, DOE, USDA, and DARPA — that the institute's compliance regime survives the transition. The grants are line-item dependent on the founder; the compliance regime is dependent on the institution.

The institutional lesson the Friday announcement carries forward is the simplest one. A private institute had its successor in the room when its founder died. The federal science advisory board did not have its successors named ten days after its body was emptied. One of those institutions ran on continuity. The other ran on assumption. Today's contrast is between what continuity buys and what assumption costs.

-- KENJI NAKAMURA, Tokyo